Table 3.
Effect of sampling method on detection of cancer
| First Biopsy Gleason Score1: | Second Biopsy: Upgrades/Biopsy Method2 | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| 3+3 (n=268) | Total | Upgrades | Systematic only | MRI Target only | Systematic Tracking only | MRI Target Tracking only |
| Systematic Only | 175 | 43 (24.6%) | 3 | 9 | 22 | 0 |
| Target Only | 41 | 13 (31.7%) | 0 | 4 | 0 | 7 |
| Both | 52 | 16 (30.8%) | 0 | 1 | 4 | 8 |
| 3+4 (n=84) | ||||||
| Systematic Only | 53 | 10 (18.9%) | 1 | 3 | 4 | 0 |
| Target Only | 28 | 7 (25.0%) | 1 | 2 | 0 | 3 |
| Both | 3 | 2 (66.7%) | 0 | 2 | 0 | 0 |
1
Systematic only: CaP only found on systematic cores. Target only: CaP only found in MRI-visible lesion. Both: CaP found on both systematic and MR-visible lesions.
2
Upgrades/biopsy method is mutually exclusive. Example: 22 upgrades were found in the Gleason score 3+3 group by systematic tracking only and by no other biopsy method.